Abstract: Suggested is a composition with stabilized taste and/or odor, comprising (a) at least one acetophenone derivative of formula (I) wherein R1 stands for hydrogen or methyl, and R2 stands for hydrogen, hydroxyl or a —OCH3 group, or a cosmetically pharmaceutically acceptable salt thereof, and (b) at least one mono- or polyunsaturated C8-C22 fatty acid or its monohydric polyhydric C1-C18 alkyl alcohols ester.

Abstract: The present disclosure provides a cosmetic cleanser that is solid at about 25° C., including—with respect to its weight—from about 5% to about 90% by weight of alkali salts of fatty acids (soaps); from about 2% to about 50% by weight of acyl glutamate(s); and from about 0.1% to about 10% by weight of betaine (N,N,N-trimethylammonioacetate or N,N,N-trimethylglycine).

Abstract: Hair treatment products comprising, in relation to its weight, from about 0.001 to about 10% by weight of at least one amine salt, of a carboxylic acid, at least one bivalent or trivalent metal salt and at least one organic acid, which lead to improved structural reinforcement of keratin fibres and improved hair care, and which reduce or prevent colour washout in dyed hair.

Abstract: The present invention relates to a process for dyeing keratin fibers, in particular human keratin fibers such as the hair, using a) one or more blue, violet or green dyes and b) one or more disulfide, thiol or protected-thiol fluorescent dyes. The present invention also relates to a cosmetic composition comprising the dyes defined above, and also to a multi-compartment device containing said dyes. The present invention also relates to the use of said dyes for dyeing light keratin fibers, notably human keratin fibers such as the hair, in chestnut-brown, dark chestnut-brown, brown, brown with a tint, or even black, without using an additional dye other than those defined above.

Abstract: The present invention is intended to provide an oily makeup cosmetic that is colorless in appearance but develops a color on application onto body surface, such as skin and lips. The present invention provides a colorless oily makeup cosmetic comprising (a) one or two dyes selected from Red No. 218 and Red No. 223, and (b) an oil agent, and a mixture of the component (a) and the component (b) at a mass ratio (a):(b) of 0.1:100 has a difference of 0.2 or less between the maximum absorbance and the minimum absorbance in a wavelength region of 500 to 600 nm. The oily makeup cosmetic may develop a color due to the component (a) on application onto body surface, such as skin and lips.

Abstract: Disclosed are compositions for treating and conditioning keratinous substrates, comprising a silane compound; hydrophobic silica aerogel particles; a first organic acid; a cationic surfactant chosen from fatty dialkylamines; a second organic acid; a fatty alcohol; water; and optionally, a silicone compound other than the silane compound. Also disclosed are methods for treating and conditioning keratinous substrates using the composition.

Abstract: The present invention provides compositions, uses and methods thereof, for inhibiting the growth of caries-causing bacteria. The composition comprises xylitol, sodium citrate, sodium bicarbonate, anionic polymers and acceptable carrier materials. The compositions can tend to be used for treating or preventing a condition caused by caries-causing bacteria The compositions can further tend to be used in patients such as children, adolescents or patients suffering from a heightened susceptibility to toxic substances.

Abstract: The present specification relates to a whitening composition including a novel compound isolated from a post-fermented tea, an isomer thereof, a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and may be widely used in various areas related to skin whitening and skin care.

Abstract: The present disclosure relates to an external-use skin preparation composition containing a natural ceramide, a ceramide derivative, and a Hibisci cortex extract, and more specifically, the present disclosure relates to an external-use skin preparation composition containing these ingredients, thereby being effective for enhancing skin moisturizing ability, reducing skin wrinkles, and enhancing elasticity. In addition, the present disclosure relates to use of the composition, and a method for improving skin moisturization, reducing skin wrinkles, and/or improving skin elasticity by using the composition.

Abstract: An object of the present invention is to provide fine particles excellent in biodegradability and touch feeling. Disclosed are cellulose acetate particles, the cellulose acetate particles have an average particle size of 80 nm or more and 100 ?m or less, a sphericity of 0.7 or more and 1.0 or less, and a surface smoothness of 80% or more and 100% or less, and the cellulose acetate has a total degree of acetyl substitution of 0.7 or more and 2.9 or less.

Abstract: A fragrance release composition comprising: (a) a polyolefin comprising polymerized units of ethylene and at least one C4-C12 alkene; and (b) a fragrance.

Abstract: The present invention relates to a composition for dyeing and/or lightening keratin fibres, in particular human keratin fibres such as the hair, comprising: a) one or more guanidine salts, b) one or more alkanolamines, c) ammonium hydroxide and d) at least two different polyols in a total content greater than or equal to 5% by weight relative to the total weight of the composition, and e) optionally one or more colouring agents. The invention also relates to a dyeing and/or lightening process using said composition, and also to a multi-compartment device which is suitable for using said dyeing and/or lightening composition.

Abstract: Powdery cosmetic compositions containing, based on their total weight a) from about 5 to about 20% by weight of hydrophobized metal oxide powder b) from about 40 to about 94% by weight of organic polyol c) from about 0.1 to about 15% by weight of emulsifier d) from about 0.1 to about 10% by weight of composite powder, including (A) powder particles of a silicone elastomer and (B) particles of silicon dioxide, wherein the particles of silicon dioxide (B) are immobilized on the surface of the powder particles of the silicone elastomer (A), and e) from 0 to about 40% by weight of water, are particularly suitable for the deformation of keratinic fibers, imparting shine, texture and suppleness, without creating a sticky feeling on the skin and/or the keratinic fibers.

Abstract: A cosmetic composition for temporarily shaping hair includes, in a cosmetically acceptable support—respectively with respect to the total weight of the composition— e) from about 0.5% to about 8% by weight of a wax with a melting point of more than about 37° C., f) from about 0.5% to about 5% by weight of a fatty alcohol, g) from about 0.2% to about 2% by weight of a vinylpyrrolidone-containing polymer or copolymer, and h) from about 0.1% to about 10% by weight of composite powder comprising (A) powdered particles of a silicone elastomer, and (B) particles of silicon dioxide, wherein the particles of silicon dioxide (B) are immobilized on the surface of the powdered particles of the silicone elastomer (A).

Abstract: Disclosed are methods of treating aging effects on a subject skin, comprising contacting the skin with a skin microbiome complex, including topical compositions containing YM Microbiome Complex and Advanced Probiotic Complex, methods of treatment using the compositions and methods of preparing the compositions for preventing, slowing, and reversing skin aging. Also disclosed are related formulations and methods of skin microbiome transplantation.

Abstract: Self-regulating, osmotic, floating gastroretentive compositions that provide extended release, delayed release, and/or delayed extended release of active pharmaceutical agents, as well as, optionally, immediate release of the same or a different active pharmaceutical agent, are provided here. The gastroretentive compositions of the disclosure comprise a swellable, extended release, multilayer core comprising a push layer and a pull layer; a water-insoluble permeable elastic membrane surrounding the multilayer core; and an orifice (e.g., a laser-drilled orifice, a manually drilled orifice) on the pull-layer side of the dosage form. The gastric retention of the composition is controlled by rapid floating of the composition and expansion of the membrane.

Abstract: An oral gel composition suitable for the treatment of oral leukoplakia comprising a combination of diclofenac with hyaluronic acid and methods of administering the oral gel that may include a device that prolongs contact time of the oral gel with the areas of the mucosa that are affected by oral leukoplakia.

Abstract: Vaporizable compositions based on specific components in cannabis extracts and in particular comprising cannabinol and optionally sleep inducing terpenes, are provided. Such compositions, comprising low to medium concentration of CBN, are particularly useful in treating sleep disorders such as insomnia.

Abstract: The present invention provides formulations that achieve effective delivery of methylnaltrexone compositions. The provided formulations are useful for preventing, treating delaying, diminishing or reducing the severity of side effects resulting from use of analgesic opioids.

Abstract: Disclosed herein are formulations and methods for reversing cannabinoid overdose or one or more symptoms thereof, comprising parenterally administering a CB1 antagonist in an amount sufficient to reverse the cannabinoid overdose or symptom(s).

Abstract: The present invention relates to a composition for preparing a microneedle, a soluble microneedle, and a microneedle percutaneous patch comprising the soluble microneedle. A soluble microneedle contained in a microneedle percutaneous patch of the present invention has a high drug loading capacity and excellent strength and thus may contain an effective amount of donepezil or a pharmaceutically acceptable salt thereof even with a small area of the microneedle. Accordingly, the present invention is economical and produces a lower level of skin irritation.

Abstract: The present invention relates to long-acting implants useful for the treatment of bacterial infections, particularly mycobacterial infections. The invention also relates to methods of use of such long-acting implants for the treatment of mycobacterial infections such as those caused by Mycobacteria tuberculosis.

Abstract: The invention relates to a drug delivery system for contraception including a steroidal estrogenic compound, a steroidal progestogenic compound or a combination thereof for the purposes of contraception in a subject, and provides for an ultra-low dose delivery of a steroidal estrogenic compound. The invention also relates to a method of contraception using the drug delivery system and method of manufacturing the drug delivery system.

Abstract: Embodiments of the invention include plant stem cell products and treatment methods using the products. In some embodiments, the products may include extracts of plant stem cells, such as apple stem cells, and an aerosolizing device configured to create an aerosol from the plant stem cell products and to deliver the aerosol to the lung via inhalation. Treatment methods include aerosol inhalation of the plant stem cell products.

Abstract: Embodiments of the invention include plant stem cell products and treatment methods using the products. In some embodiments, the products may include extracts of plant stem cells, such as apple stem cells, and an aerosolizing device configured to create an aerosol from the plant stem cell products and to deliver the aerosol to the lung via inhalation. Treatment methods include aerosol inhalation of the plant stem cell products.

Abstract: Disclosed is a pharmaceutical composition useful as an appetite suppressant. Disclosed also is a process for the suppression of appetite and/or for the treatment and/or prevention of obesity.

Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Abstract: Methods of treating a heart condition include administering by inhalation an effective amount of at least one antiarrhythmic pharmaceutical agent to a patient in need thereof. Nebulized drug product and kits are also contemplated.

Abstract: The invention relates to a hydrogel matrix comprising a mixture of a covalent peptide-polymer conjugate and an oligosaccharide; wherein the oligosaccharide is a highly negatively charged sulfated oligosaccharide selected from the group consisting of heparin, dextran sulfate, ?-cyclodextrin sulfate, ?-cyclodextrin sulfate and ?-cyclodextrin sulfate; wherein said polymer comprised in said peptide-polymer conjugate is a linear or multi-arm polyethylene glycol; wherein said peptide comprised in said peptide-polymer conjugate is a peptide, which consists of an amino acid sequence selected from the group consisting of SEQ ID NO.4, SEQ ID NO.5, SEQ ID NO. 18 and SEQ ID NO. 19; and wherein said hydrogel matrix is configured in the form of an oligosaccharide/peptide/polymer system, in which said peptide is chemically conjugated to the polymer such that the hydrogel is obtained by mixing the peptide-polymer conjugate and the oligosaccharide.

Abstract: This disclosure is directed to an ophthalmic formulation for dry eye and other ocular indications that provides long-lasting benefits. The formulations described herein provide durable relief and last two to ten longer on the eye than currently marketed products. The disclosure also provides methods of alleviating the symptoms of dry eye, methods for delivering ophthalmic pharmaceuticals, and methods of manufacture of the long-lasting ophthalmic formulations.

Abstract: The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a curcumin molecule or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent. In another embodiment, the present invention provides a method of treating cancer by administering a therapeutically effective amount of a composition comprising a micelle construct attached to curcumin or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent.

Abstract: A “nanolipogel” is a delivery vehicle including one or more lipid layer surrounding a hydrogel core, which may include an absorbent such as a cyclodextrin or ion-exchange resin. Nanolipogels can be constructed so as to incorporate a variety of different chemical entities that can subsequently be released in a controlled fashion. These different incorporated chemical entities can differ dramatically with respect to size and composition. Nanolipogels have been constructed to contain co-encapsulated proteins as well as small hydrophobic drugs within the interior of the lipid bilayer. Agents incorporated within nanolipogels can be released into the milieu in a controlled fashion, for example, nanolipogels provide a means of achieving simultaneous sustained release of agents that differ widely in chemical composition and molecular weight. Additionally, nanolipogels can favorably modulate biodistribution.

Abstract: The present invention discloses c-MYC-siRNA formulation as a potential therapeutic target for cisplatin-resistant ovarian cancer. It is disclosed targeting c-MYC with small interfering RNA (siRNA) in the cisplatin-resistant ovarian cancer cell line inducing a significant cell growth arrest and inhibition of cell proliferation. Apoptosis and arrest of cell cycle progression were also observed after c-MYC-siRNA-based silencing of c-MYC. Furthermore, delivering nanoliposomal c-MYC-siRNA, decreased tumor weight and number of tumor nodules compared with a liposomal-negative control siRNA.

Abstract: The present invention provides microparticle compositions comprising anti-angiogenic peptides, as well as methods of treatment, including for macular degeneration.

Abstract: A drug carrier carrying an active substance and a method preparing the same are provided. The method includes respectively dissolving a negatively charged polymer, sodium tripolyphosphate, and an active substance in a NaOH aqueous solution to increase the encapsulation rate of the active substance in the drug carrier.

Abstract: The present invention relates in part to novel drug delivery particles comprising an anionic polymer matrix and a cationic polymer, wherein the anionic polymer matrix and cationic polymer together form drug delivery particles bound by electrostatic interactions and wherein the drug delivery particles comprise at least one biologically active agent. The invention also relates in part to a method of treating a mycobacterial infection using said drug delivery particles, and a method of making said drug delivery particles.

Abstract: The present invention refers to pellets comprising pharmaceutically active ingredient and binder. Further, the invention refers to a process for preparing said pellets, to the use of said pellets for preparing a pharmaceutical composition, and to a dosage form comprising said pellets or pharmaceutical composition. Finally, the present invention refers to a dosage from for use in a method of treating a disease selected from the group consisting of gastro esophageal reflux disease, peptic ulcer disease, and Zollinger-Ellison syndrome and for prevention of upper gastrointestinal bleeding in people who are at high risk.

Abstract: The present invention relates to a process for lyophilising a product (3), comprising the steps of providing a bulk product (3) loading system in the form of a bag (1), the bag (1) having an interior and an exterior defined by a flexible wall, the bag (1) further comprising a filling port (5) providing access to the interior of the bag (1), filling a product (3) having a first moisture content into the interior of the bag (1) via the filling port (5), and exposing the product (3) in the interior of the bag (1) to a lyophilisation cycle such that the moisture content of the product (3) is reduced from the first moisture content to a second, lower, moisture content.

Abstract: Several methods for the preparation of an amorphous powder that includes a 1:1 stoichiometric mixture of the trisodium salts of Valsartan and Sacubitril are described, as well as the resulting amorphous powder, pharmaceutical compositions containing it, and their use in the treatment of essential hypertension and/or cardiac failure.

Abstract: The instant invention relates to pharmaceutical compositions comprising doravirine, tenofovir disoproxil fumarate and lamivudine. These compositions are useful for the treatment of HIV infection. Also disclosed are processes for making said pharmaceutical compositions.

Abstract: In exemplary embodiments, the disclosure provides a Colesevelam Colon Specific Drug Delivery System for use in treatment of, for example, cholestasis and/or cholestatic pruritus.

Abstract: An aqueous composition for making dip-molded comestible hard capsules comprising a film forming capsule base material and one or more colorants each consisting of a hydrophilic coloring foodstuff concentrate.

Abstract: The present disclosure provides layer-by-layer compositions comprising a plurality of polymer bilayers. Each bilayer comprises a poly(N-vinylpyrrolidone) hydrogen-bonded a polyphenol (tannic acid) layer. In the compositions, at least one poly(N-vinylpyrrolidone) has conjugated thereon a plurality of manganoporphyrin moieties. The layer-by-layer compositions can be deposited on the cell aggregate surface or deposited on an underlying surface such as that of a silica core which, when removed creates a capsule having a hollow space for the addition of such as a therapeutic agent.

Abstract: The theranostic biocompatible microcapsules provided are efficient contrast enhanced imaging agents that combine Magnetic Resonance Imaging (MRI) with ultrasound-triggered drug release for real-time tracking and targeted delivery in vivo. The capsules are assembled via layer-by-layer deposition of the natural polyphenol tannic acid and poly(N-vinylpyrrolidone) with iron oxide nanoparticles incorporated in the capsule wall. The nanoparticle-modified capsules exhibit enhanced T1 and T2 MRI contrast in a clinical MRI scanner. Loaded with the an anticancer drug such as doxorubicin the capsules circulate in the blood stream for at least 48 hours, an improvement compared to non-encapsulated nanoparticles. High-intensity focused ultrasound results in targeted drug release with a 16-fold increase in the pharmacologically active agent localization in tumors compared to off-target organs.

Abstract: Click chemistry groups attached to both nanoparticles and antibodies to reduce antibody concentration in the body. The nanoparticles with attached click chemistry groups react with the antibody/biologic attached with a corresponding click chemistry group to sequester it in the liver and spleen, effectively and rapidly decreasing the concentration of free antibody/biologic.

Abstract: Hemostatic compositions including a combination of more than one hemostatic agent, and devices coated or impregnated therewith, have been developed. Nanotechnology yields hemostatic agents with large surface areas thereof, thereby increasing the hemostatic properties of the device to which they are applied. By combining more than one hemostatic agent and utilizing one or more different nanotechnology approaches to enhance the surface areas thereof, the capability of the dressing to stop bleeding is improved via more than one mechanism, and thus provides better hemostasis.

Abstract: The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of asenapine comprising an asenapine-containing layer structure, said asenapine-containing layer structure comprising A) a backing layer and B) an asenapine-containing layer, wherein the transdermal therapeutic system comprises a silicone acrylic hybrid polymer.

Abstract: A composition comprises ?-pinene, borneol, cinnamic aldehyde, citral, d-limonene, eucalyptol, eugenol, farnesol, linalool, thymol, and vanillin. In addition, a method for use of the composition as an antibacterial and antiviral agent is also disclosed.

Abstract: A formulation consisting of Thymol Iodide, in a Lanolin, Petrolatum, Zinc Oxide, Olive Oil base is applied to a topical skin lesion. Observed also and after discussions with patients, caregivers and patient relatives, it was discovered that a certain formulation consisting of an active pharmaceutical ingredient together with a specific base formulation promoted curing and accelerated healing of a variety of conditions. This formulation was examined for its superior effectiveness leading to the discovery found within this patent application. Such a formulation will have a drastic reduction of healthcare costs because the topical application of this formulation will effect improvement, cure and accelerated healing resulting in no need for costly operations, hospitalizations, or long-term treatment.

Abstract: The present invention provides compositions and methods of their use in treating muscular dystrophy and other disorders.